Lipidome and Microbiome Profile of the Eye in Rosacea

• Status: Active, not recruiting
• Trial end date: 2021-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The question that the investigators aim to address in this proposal is how the local lipid mediator profiles of ceramides and eicosanoids are altered in cutaneous and ocular rosacea and how antibiotics alter the lipidome. The investigators also seek to understand how the microbiome is changed in those with and without rosacea, and how the microbiome is altered in those with rosacea. Understanding how the lipidome is modulated in rosacea with antibiotic treatment will serve as the first step in targeting therapies toward directly altering the lipidome to reduce inflammation and ultimately reduce the use of antibiotics.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of California, Davis
• Treatments: Doxycycline

Criteria

Inclusion Criteria for subjects:

• Aged 18 and older

• Subjects that meet one of the following criteria:

• Healthy subjects without an inflammatory facial rash or an inflammatory eye condition

• Subjects diagnosed with ocular rosacea or cutaneous rosacea (papulopustular or erythematotelangiectatic) by either a board-certified dermatologist or ophthalmologist

Exclusion Criteria

• Those who are prisoners or cognitively impaired.

• Those who have had any change to their hormonal birth control regimen in the last 4 weeks

• Systemic antibiotic use in the last four weeks

• Allergy or known intolerance to tetracyclines

• Those who wear contact lenses

• Autoimmune disease such as lupus, dermatomyositis that has cutaneous involvement

• Those who are pregnant or may become pregnant